Elimination of ioversol by hemodialysis.
OBJECTIVE
The dialysability of ioversol was investigated in 12 patients with chronic renal failure, on 4-h hemodialysis.


METHODS
One hundred ml of ioversol (320 mg I/ml) was injected in less than 10 min during CT. Hemodialysis was commenced within 30 min of starting the contrast medium injection and was continued for 4 h. Blood was sampled before and at 15 min, 30 min, 1 h, 2 h, and 4 h after the start of hemodialysis. Mean dialysance of ioversol was 114 to 129 ml/min and the elimination rate was 82.5 +/- 5.1% 4 h after starting hemodialysis. The half-life of ioversol during hemodialysis was 1.80 +/- 0.38 h. The only side effects of the ioversol injection were heat sensations, which were experienced by 3 patients.


RESULTS
As ioversol was effectively removed from the body during the 4 h of hemodialysis and no severe adverse reactions were observed, we conclude that ioversol is suitable for use in hemodialyzed patients.
Ueda
J
J
Department of Radiology, Sumitomo Hospital, Osaka, Japan.
Furukawa
T
T
Takahashi
S
S
Sakaguchi
K
K
D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D014283:Triiodobenzoic Acids / Q000493:pharmacokinetics*
D003287:Contrast Media; D014283:Triiodobenzoic Acids; C054871:ioversol